Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clene ( (CLNN) ) has issued an update.
Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced its third quarter 2024 financial results, highlighting a meeting with the FDA to discuss accelerated approval for its ALS treatment CNM-Au8. The company raised $7.3 million through stock offerings and amended its debt agreement to extend its financial runway into early 2025. Despite a net loss of $8 million, Clene aims to continue its groundbreaking work in improving neuronal health.
Find detailed analytics on CLNN stock on TipRanks’ Stock Analysis page.